Header Logo

Connection

NATHAN FOWLER to Lymphoma, Mantle-Cell

Back to Details
This is a "connection" page, showing publications NATHAN FOWLER has written about Lymphoma, Mantle-Cell.
NATHAN FOWLER
Connection Strength
2.144
Lymphoma, Mantle-Cell
  1. Indolent and mantle cell NHL: the future is BRIGHT. Blood. 2014 May 08; 123(19):2905-6.
    View in: PubMed
    Score: 0.307
  2. Unmet needs in the treatment of mantle cell lymphoma. Clin Adv Hematol Oncol. 2013 Nov; 11(11 Suppl 18):1-19.
    View in: PubMed
    Score: 0.296
  3. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program. 2013; 2013:553-60.
    View in: PubMed
    Score: 0.279
  4. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 2023 10 12; 13(1):156.
    View in: PubMed
    Score: 0.147
  5. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
    View in: PubMed
    Score: 0.131
  6. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212.
    View in: PubMed
    Score: 0.129
  7. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629.
    View in: PubMed
    Score: 0.116
  8. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050.
    View in: PubMed
    Score: 0.115
  9. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018 11; 183(4):578-587.
    View in: PubMed
    Score: 0.103
  10. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018 08; 182(3):404-411.
    View in: PubMed
    Score: 0.101
  11. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
    View in: PubMed
    Score: 0.101
  12. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100.
    View in: PubMed
    Score: 0.094
  13. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179.
    View in: PubMed
    Score: 0.081
  14. Integrating emerging treatment options in mantle cell lymphoma. Clin Adv Hematol Oncol. 2013 Dec; 11(12 Suppl 19):1-15.
    View in: PubMed
    Score: 0.074
  15. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23.
    View in: PubMed
    Score: 0.067
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.